Bavarian Nordic Partners with Biological E Limited to Expand Global Access to Chikungunya Vaccine

Posted: February 25, 2025 at 2:45 am

COPENHAGEN, Denmark, February 25, 2025 – Bavarian Nordic A/S (OMX: BAVA) today announced a strategic partnership with Biological E. Limited (BE) to expand access to Bavarian Nordic’s chikungunya vaccine in low- and middle-income (LMIC) countries.

Visit link:
Bavarian Nordic Partners with Biological E Limited to Expand Global Access to Chikungunya Vaccine

Related Posts